Position in GSK
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$2,670,327
+$254,882 QoQ
Shares Held
50,941
+16.4% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.68%
of 13F equity value
Holder Rank
#215
of 1,033 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in GSK Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Kendall Capital Management holds $22,925,368 across 11 Drug Manufacturers - General names. GSK ranks #3 (11.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABBV |
AbbVie Inc.
|
24,818 | $6,245,201 | |
| 2 | BMY |
Bristol Myers Squibb Co
|
69,150 | $3,984,423 | |
| 3 | GSK |
GSK plc
This page
|
50,941 | $2,670,327 | |
| 4 | MRK |
Merck & Co., Inc.
|
19,682 | $2,529,137 | |
| 5 | JNJ |
Johnson & Johnson
|
8,136 | $2,066,299 | |
| 6 | PFE |
Pfizer Inc
|
49,545 | $1,193,043 | |
| 7 | AMGN |
Amgen Inc
|
2,995 | $1,084,549 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
8,362 | $1,056,455 |
All Filings in GSK
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,670,327 | 50,941 | Shares | Sole | 2026-08-12 | |
| 2026-03-31 | $2,415,445 | 43,766 | Shares | Sole | 2026-04-24 | |
| 2025-12-31 | $2,057,522 | 41,956 | Shares | Sole | 2026-01-16 | |
| 2025-09-30 | $1,421,733 | 32,941 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $977,126 | 25,446 | Shares | Sole | 2025-07-16 | |
| 2025-03-31 | $557,701 | 14,396 | Shares | Sole | 2025-04-25 | |
| No filing history on record for this holder in this stock. | ||||||